Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00418613 | A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED) | PHASE2 | COMPLETED | 266 | — | — | Jan 1, 2008 | Mar 1, 2009 | Sep 3, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK0633 |
| 2 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MK633 | DRUG | MK0633 100mg capsules qd for a 12-wk treatment period. |
| Comparator: Placebo (unspecified) | DRUG | MK0633 100mg Pbo capsules for a 12-wk treatment period |
Inclusion Criteria: * Documented COPD defined by clinical history and spirometry, with symptoms including dyspnea, wheezing, chest tightness, cough, sputum production, or nocturnal awakening * Male or postmenopausal females 40 -75 years of age Exclusion Criteria: * Impaired renal function * Histo...